Today, we will study why ChemoCentryx (CCXI) is a promising investment opportunity in 2020.
Company overview
ChemoCentryx is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune diseases, inflammatory disorders, and cancer. The majority of the therapies are targeting orphan and rare disease indications in these segments. The company's investigational small molecule therapies are targeting the body's chemokines and chemoattractant system.
What is ChemoCentryx's guiding scientific principle?
Inflammation can be categorized as local or systemic and acute or chronic. This condition is a response of the body's vascularized tissue to